Literature DB >> 20798697

Evolving role of 5-alpha reductase inhibitors in chemoprevention.

Wesley M White, Edward D Kim.   

Abstract

Mesh：

Substances：

Year:  2010        PMID： 20798697     DOI： 10.1038/nrclinonc.2010.114

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  9 in total

Review 1.  Prostate cancer.

Authors:  William G Nelson; Angelo M De Marzo; William B Isaacs
Journal:  N Engl J Med       Date:  2003-07-24       Impact factor: 91.245

2.  Three considerations before advising 5-alpha-reductase inhibitors for chemoprevention.

Authors:  Patrick C Walsh
Journal:  J Clin Oncol       Date:  2009-06-01       Impact factor: 44.544

3.  Effect of dutasteride on the risk of prostate cancer.

Authors:  Gerald L Andriole; David G Bostwick; Otis W Brawley; Leonard G Gomella; Michael Marberger; Francesco Montorsi; Curtis A Pettaway; Teuvo L Tammela; Claudio Teloken; Donald J Tindall; Matthew C Somerville; Timothy H Wilson; Ivy L Fowler; Roger S Rittmaster
Journal:  N Engl J Med       Date:  2010-04-01       Impact factor: 91.245

4.  Effect of finasteride on the sensitivity of PSA for detecting prostate cancer.

Authors:  Ian M Thompson; Chen Chi; Donna Pauler Ankerst; Phyllis J Goodman; Catherine M Tangen; Scott M Lippman; M Scott Lucia; Howard L Parnes; Charles A Coltman
Journal:  J Natl Cancer Inst       Date:  2006-08-16       Impact factor: 13.506

Review 5.  Chemoprevention of prostate cancer.

Authors:  Andrew J Stephenson; Robert Abouassaly; Eric A Klein
Journal:  Urol Clin North Am       Date:  2010-02       Impact factor: 2.241

6.  Pathologic characteristics of cancers detected in The Prostate Cancer Prevention Trial: implications for prostate cancer detection and chemoprevention.

Authors:  M Scott Lucia; Amy K Darke; Phyllis J Goodman; Francisco G La Rosa; Howard L Parnes; Leslie G Ford; Charles A Coltman; Ian M Thompson
Journal:  Cancer Prev Res (Phila)       Date:  2008-05-18

7.  The influence of finasteride on the development of prostate cancer.

Authors:  Ian M Thompson; Phyllis J Goodman; Catherine M Tangen; M Scott Lucia; Gary J Miller; Leslie G Ford; Michael M Lieber; R Duane Cespedes; James N Atkins; Scott M Lippman; Susie M Carlin; Anne Ryan; Connie M Szczepanek; John J Crowley; Charles A Coltman
Journal:  N Engl J Med       Date:  2003-06-24       Impact factor: 91.245

Review 8.  Use of 5alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline.

Authors:  Barnett S Kramer; Karen L Hagerty; Stewart Justman; Mark R Somerfield; Peter C Albertsen; William J Blot; H Ballentine Carter; Joseph P Costantino; Jonathan I Epstein; Paul A Godley; Russell P Harris; Timothy J Wilt; Janet Wittes; Robin Zon; Paul Schellhammer
Journal:  J Urol       Date:  2009-02-26       Impact factor: 7.450

9.  Cost-effectiveness of prostate cancer chemoprevention: a quality of life-years analysis.

Authors:  Robert S Svatek; J Jack Lee; Claus G Roehrborn; Scott M Lippman; Yair Lotan
Journal:  Cancer       Date:  2008-03-01       Impact factor: 6.860
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.